ReviewCurrent rheumatology reports2013
The immune pathogenesis of scleroderma: context is everything.
Review in Current rheumatology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03059979 (Hit Hard and Early. The Effect of High Dose Methylprednisolone on Nailfold Capillary Changes and Biomarkers in Early SSc), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Hit Hard and Early. The Effect of High Dose Methylprednisolone on Nailfold Capillary Changes and Biomarkers in Early SSc: a 12-week Randomised Explorative Double-blind Placebo-controlled Trial.
Who cites it
24 citing papers in PubMed.
- Efficacy of methylprednisolone in very early systemic sclerosis: results of the 'Hit Hard and Early' randomized controlled trial.Rheumatology (Oxford, England) · 2025Trial
- Performance of a new quantitative computed tomography index for interstitial lung disease assessment in systemic sclerosis.Scientific reports · 2019Trial
- Trial
- Article
- Kidney Involvement in Systemic Sclerosis.Journal of personalized medicine · 2022Review
- Th17 cell-derived miR-155-5p modulates interleukin-17 and suppressor of cytokines signaling 1 expression during the progression of systemic sclerosis.Journal of clinical laboratory analysis · 2022Article
- IL-4 and CCR7 play an important role in the development of keloids in patients with a family history.American journal of translational research · 2022Article
- Observational
- The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets.Archives of dermatological research · 2020Review
- RNA Sequencing Keloid Transcriptome Associates Keloids With Th2, Th1, Th17/Th22, and JAK3-Skewing.Frontiers in immunology · 2020Article
- pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis.JCI insight · 2018Article
- Esophageal high-resolution impedance manometry alterations in asymptomatic patients with systemic sclerosis: prevalence, associations with disease features, and prognostic value.Clinical rheumatology · 2018Article
- Interleukin-33 in Systemic Sclerosis: Expression and Pathogenesis.Frontiers in immunology · 2018Review
- Gastrointestinal Manifestations of Systemic Sclerosis.Rheumatology (Sunnyvale, Calif.) · 2018Article
- Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patients.Stem cell research & therapy · 2017Article
- A modified graft-versus-host-induced model for systemic sclerosis, with pulmonary fibrosis in Rag2-deficient mice.FEBS open bio · 2017Article
- The IL-33 gene is related to increased susceptibility to systemic sclerosis.Rheumatology international · 2016Article
- Membrane array and multiplex bead analysis of tear cytokines in systemic sclerosis.Immunologic research · 2016Article
- Update on macrophages and innate immunity in scleroderma.Current opinion in rheumatology · 2015Review
- Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The fundamental mechanisms that drive the pathogenesis of systemic sclerosis (SSc) remain elusive, despite over 50 years of investigation. Here, we review recent progress in the understanding of the immunopathogenesis of SSc. In particular, we consider interleukin-13 (IL13), and its upstream and downstream pathways, as an example of an immune system-derived mediator involved in fibrotic and vascular pathology. Emerging results linking pattern-recognition receptors and interferon pathways to SSc are also stressed. We discuss genetic data linking the immune system to SSc risk and efforts to apply animal models to subsets of patients recently resolved by gene expression profiling. These developments will help build a context for better understanding of previous observations and design of the next generation of studies that may eventually lead to effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.